Avalo Therapeutics (AVTX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$111.6 million.
- Avalo Therapeutics' Enterprise Value fell 3635.44% to -$111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$111.6 million, marking a year-over-year decrease of 3635.44%. This contributed to the annual value of -$134.5 million for FY2024, which is 171451.11% down from last year.
- Per Avalo Therapeutics' latest filing, its Enterprise Value stood at -$111.6 million for Q3 2025, which was down 3635.44% from -$113.3 million recorded in Q2 2025.
- Avalo Therapeutics' Enterprise Value's 5-year high stood at -$6.3 million during Q2 2023, with a 5-year trough of -$134.5 million in Q4 2024.
- For the 5-year period, Avalo Therapeutics' Enterprise Value averaged around -$57.6 million, with its median value being -$40.4 million (2021).
- In the last 5 years, Avalo Therapeutics' Enterprise Value soared by 7630.55% in 2022 and then tumbled by 171451.11% in 2024.
- Avalo Therapeutics' Enterprise Value (Quarter) stood at -$54.6 million in 2021, then surged by 75.87% to -$13.2 million in 2022, then soared by 43.71% to -$7.4 million in 2023, then tumbled by 1714.51% to -$134.5 million in 2024, then grew by 17.04% to -$111.6 million in 2025.
- Its last three reported values are -$111.6 million in Q3 2025, -$113.3 million for Q2 2025, and -$125.0 million during Q1 2025.